GlaxoSmithKline (GSK) announced a change to the business focus and organisational structure of its pharmaceutical division, based in Melbourne, yesterday.
These changes will result in the reduction of about 90 positions from the pharmaceutical business, but will not impact manufacturing.
Geoff McDonald, GSK’s general manager pharmaceuticals said the job cuts came as a result of difficult conditions in the Australian market.
“Funding for medicines is currently very challenging in Australia,” he said.
“We have changed our business strategy to ensure that patients are able to access new treatment options as they emerge from our global pipeline which has seen exceptional progress this year.”
GSK in Australia consists of two main divisions (Pharmaceuticals and Consumer Healthcare) and four manufacturing facilities.
GlaxoSmithKline (GSK) announced a change to the business focus and organisational structure of its pharmaceutical division, based in Melbourne, yesterday.
These changes will result in the reduction of about 90 positions from the pharmaceutical business, but will not impact manufacturing.
Geoff McDonald, GSK’s general manager pharmaceuticals said the job cuts came as a result of difficult conditions in the Australian market.
“Funding for medicines is currently very challenging in Australia,” he said.
“We have changed our business strategy to ensure that patients are able to access new treatment options as they emerge from our global pipeline which has seen exceptional progress this year.”
GSK in Australia consists of two main divisions (Pharmaceuticals and Consumer Healthcare) and four manufacturing facilities.
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.